Skip to content
OpenCapital
Get started

Utah Medical Products UTMD Share-Based Payment - Unrecognized Cost of Nonvested Awards

Share-Based Payment - Unrecognized Cost of Nonvested Awards at other companies

UFP Technologies logo
UFP TechnologiesUFPT
$14.7M—
Stereotaxis logo
StereotaxisSTXS
$2M-13.0%
Medline, Inc. logo
Medline, Inc. MDLN
——

Other financials

Income statement

See full
Revenue$8.7M-10.2%
Gross profit$5.3M-4.6%
Operating income$2.6M-18.6%
Net income$2.6M-14.4%
EPS (diluted)$0.82-10.9%

Balance sheet

See full
Cash & equivalents$87.4M+4.9%
Total debt$210.0K—
Total equity$120.4M+2.8%
Total assets$124.4M+1.5%

Cash flow

See full
Operating cash flow$3.1M-30.4%
CapEx$130.0K-29.3%
Free cash flow$3.0M-30.4%

Valuation

See full
Market cap$219.63M+26.4%
Enterprise value$132.44M+42.5%
P/E20.3×+6.4×
P/S5.9×+1.4×

Profitability

See full
Gross margin57.9%-0.4pp
Operating margin28.8%-3.9pp
Net margin28.9%-4.1pp
FCF margin34.7%0.0pp

Returns & leverage

See full
Return on equity9.1%-1.4pp
Debt / equity0×—
Current ratio28.6×+6.3×

Where this comes from

Reported directly by Utah Medical Products in its filing.

Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.

The official record: Utah Medical Products’s 10-K, filed March 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Utah Medical Products's share-based payment - unrecognized cost of nonvested awards.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Utah Medical Products's share-based payment - unrecognized cost of nonvested awards?
Utah Medical Products (UTMD) reported share-based payment - unrecognized cost of nonvested awards of $1.01M in Q4 2025.
How has Utah Medical Products's share-based payment - unrecognized cost of nonvested awards changed year-over-year?
Utah Medical Products's share-based payment - unrecognized cost of nonvested awards increased by 12.9% year-over-year, from $898K to $1.01M.
What is the long-term trend for Utah Medical Products's share-based payment - unrecognized cost of nonvested awards?
Over 5 years (2020 to 2025), Utah Medical Products's share-based payment - unrecognized cost of nonvested awards has grown at a 18.6% compound annual growth rate (CAGR), from $432K to $1.01M.
What does share-based payment - unrecognized cost of nonvested awards mean?
This represents the total compensation expense for equity-based awards that has been granted but not yet recognized in the income statement because the vesting conditions have not been met. It serves as a forward-looking indicator of future non-cash compensation expenses. Investors use this to forecast the impact of stock-based compensation on future earnings.